Intriguingly, recent work suggested that the first-line anti-HCC drug sorafenib induced HIF-2α expression, whereas treating with the HIF-2 antagonist PT2385 significantly reversed sorafenib efficiency [30]. The gene discussed is EPAS1; the disease is hepatocellular carcinoma.